TMIGD2 and neoplasm: In line with this, CD107a degranulation assays revealed enhanced cytotoxic granule release in mGM3/CD28H cells (Figures 1K, L), and cytotoxicity assays demonstrated consistently higher tumor-killing efficiency across all tested effector-to-target (E:T) ratios (Figure 1M).